News

Data from a pair of phase 3 trials suggest that tirzepatide treatment may improve patient-reported measures of sleepiness in individuals with obstructive sleep apnea and obesity.

Prespecified analyses showed that obicetrapib significantly reduced primary outcome measure of Alzheimer disease biomarkers in both the overall population and APOE4 carriers.

New phase 2 trial data presented at SLEEP 2025 suggest TAK-861 significantly decreased microsleep frequency and delayed onset of first microsleep in individuals with narcolepsy type 1.

New analysis reveals insights on hypnagogic and hypnopompic hallucinations in narcolepsy patients treated with once-nightly sodium oxybate.

Catch up on any of the neurology news headlines you may have missed over the course of May 2025, compiled all into one place by the NeurologyLive® team.

A newly presented actigraphy-based algorithm demonstrated high accuracy in detecting daytime naps, offering insights into napping behavior changes in patients with narcolepsy type 1.

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

A new study presented at SLEEP 2025 reported that more than one-quarter of pregnant women experienced restless legs syndrome, with prior history of the condition emerging as a significant risk factor.

New research reveals solriamfetol significantly enhances neuropsychological outcomes in patients with obstructive sleep apnea and excessive daytime sleepiness.

A newly presented study at SLEEP 2025 explored the practicality of various methods, such as the Apple Watch and polysomnogram, for assessing sleep in pediatric patients with Lennox-Gastaut syndrome.

Here's some of what is coming soon to NeurologyLive® this week.

A new study evaluates the effectiveness and safety of once-nightly sodium oxybate for narcolepsy, aiming to enhance patient treatment experiences.

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.

A patient and neurologist discussed personal and professional perspectives on treatment initiation, ongoing research, and patient advocacy in multiple sclerosis. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the care of parasomnias.

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.

A patient and neurologist discussed the importance of individualized treatment strategies and the role of shared decision-making in managing multiple sclerosis. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending June 7, 2025. [WATCH TIME: 4 minutes]

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 6, 2025.

A patient living with MS and MS clinical expert reflected on the varied and often-misdiagnosed early symptoms that can signal the onset of the autoimmune disease. [WATCH TIME: 6 minutes]

Ahmed Abdelhak, MD, assistant professor of neurology at the UCSF, discussed the evolving landscape of biomarkers in multiple sclerosis and their potential to transform remyelination approaches.

A recent study revealed that rizatriptan was ineffective for treating vestibular migraine attacks, showing limited symptom relief compared with placebo.

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

New data reveals RGX-202 gene therapy shows significant improvements in Duchenne muscular dystrophy patients, enhancing disease management and safety.

A patient living with MS and MS clinical expert reflected on the varied and often-misdiagnosed early symptoms that can signal the onset of the autoimmune disease. [WATCH TIME: 6 minutes]

Phil Lambert, PhD, chief scientific officer at Satellos Bioscience, discusses the rationale and early clinical progress of SAT-3247, a novel regenerative therapy targeting muscle stem cells in Duchenne muscular dystrophy.

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health highlighted the significant impact of loneliness in individuals with multiple sclerosis. [WATCH TIME: 6 minutes]